[{"id":"a9fb190d-5040-4b41-93e3-ee7c0f5f1fc3","acronym":"MK3475-C01","url":"https://clinicaltrials.gov/study/NCT05304546","created_at":"2022-03-31T17:52:51.205Z","updated_at":"2024-07-02T16:35:46.583Z","phase":"Phase 2","brief_title":"Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma","source_id_and_acronym":"NCT05304546 - MK3475-C01","lead_sponsor":"Dr. Ronnie Shapira","biomarkers":" MYC • CD8 • CTLA4 • ACAT1","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF V600K","tags":["MYC • CD8 • CTLA4 • ACAT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Mektovi (binimetinib) • Braftovi (encorafenib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 06/01/2023","start_date":" 06/01/2023","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2023-06-05"},{"id":"83ba0960-d9f7-451f-82ac-c2370e0d4cec","acronym":"","url":"https://clinicaltrials.gov/study/NCT04203459","created_at":"2021-01-18T20:28:45.574Z","updated_at":"2024-07-02T16:36:52.278Z","phase":"","brief_title":"The Mechanism of Enhancing the Anti-tumor Effects of CAR-T on PC by Gut Microbiota Regulation","source_id_and_acronym":"NCT04203459","lead_sponsor":"First Affiliated Hospital of Harbin Medical University","biomarkers":" CD8 • MSLN • TNFA • ACAT1","pipe":"","alterations":" ","tags":["CD8 • MSLN • TNFA • ACAT1"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 10/20/2019","start_date":" 10/20/2019","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 12/31/2022","study_completion_date":" 12/31/2022","last_update_posted":"2019-12-18"}]